With that in mind, let's take a closer look at Merck and see what CAPS investors are saying about the stock right now.
Whitehouse Station, N.J. (1891)
Chairman/CEO Kenneth Frazier
Return on Equity (average, past 3 years)
Cash / Debt
$16.0 billion / $20.8 billion
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 93% of the 2,928 members who have rated Merck believe the stock will outperform the S&P 500 going forward.
Long-term outperform for a steady Eddie in a strong industry.
-Incredibly strong drug pipeline
-3.6% [dividend yield]
-Broad demographic shift toward more demand for their goods
-Somewhat expensive, but justified, as it is a great defensive selection
5+ year outperform as Merck looks to reinvigorate its sales with 6 quality drugs in its pipeline.
Still in the dark about how Obamacare might affect you and your portfolio? Don't worry -- you're not alone. To help prepare investors for the massive changes coming to the American health care system, The Motley Fool created a special free report that makes this complex topic easily understandable. Download "Everything You Need to Know About Obamacare" and discover how the law may impact your taxes, health insurance, and investments. Click here for your free copy today.
The article Why Merck Is Poised to Pop originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.